Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Krystle A. Lang Kuhs; Michael Pawlita; Sandra P. Gibson; Nicole C. Schmitt; Sumita Trivedi; Athanassios Argiris; Aimée R. Kreimer; Robert L. Ferris; Tim Waterboer

doi:10.1016/j.canep.2016.03.003

Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Krystle A. Lang Kuhs, Michael Pawlita, Sandra P. Gibson, Nicole C. Schmitt, Sumita Trivedi, Athanassios Argiris, Aimée R. Kreimer, Robert L. Ferris, Tim Waterboer

School of Medicine

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

Original language	English (US)
Pages (from-to)	46-52
Number of pages	7
Journal	Cancer Epidemiology
Volume	42
DOIs	https://doi.org/10.1016/j.canep.2016.03.003
State	Published - Jun 1 2016

Keywords

HPV antibodies
HPV seropositivity
HPV16
HPV16 E6
Human papillomavirus 16
Non-OPC
Non-oropharyngeal cancer
OPC
Oropharyngeal cancer

ASJC Scopus subject areas

Epidemiology
Oncology
Cancer Research

Access to Document

10.1016/j.canep.2016.03.003

Cite this

@article{143c68d2894e444988cc2231de098ba5,

title = "Characterization of human papillomavirus antibodies in individuals with head and neck cancer",

abstract = "Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.",

keywords = "HPV antibodies, HPV seropositivity, HPV16, HPV16 E6, Human papillomavirus 16, Non-OPC, Non-oropharyngeal cancer, OPC, Oropharyngeal cancer",

author = "{Lang Kuhs}, {Krystle A.} and Michael Pawlita and Gibson, {Sandra P.} and Schmitt, {Nicole C.} and Sumita Trivedi and Athanassios Argiris and Kreimer, {Aim{\'e}e R.} and Ferris, {Robert L.} and Tim Waterboer",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.canep.2016.03.003",

language = "English (US)",

volume = "42",

pages = "46--52",

journal = "Cancer Epidemiology",

issn = "1877-7821",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Characterization of human papillomavirus antibodies in individuals with head and neck cancer

AU - Lang Kuhs, Krystle A.

AU - Pawlita, Michael

AU - Gibson, Sandra P.

AU - Schmitt, Nicole C.

AU - Trivedi, Sumita

AU - Argiris, Athanassios

AU - Kreimer, Aimée R.

AU - Ferris, Robert L.

AU - Waterboer, Tim

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

AB - Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.

KW - HPV antibodies

KW - HPV seropositivity

KW - HPV16

KW - HPV16 E6

KW - Human papillomavirus 16

KW - Non-OPC

KW - Non-oropharyngeal cancer

KW - OPC

KW - Oropharyngeal cancer

UR - http://www.scopus.com/inward/record.url?scp=84961786714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961786714&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2016.03.003

DO - 10.1016/j.canep.2016.03.003

M3 - Article

C2 - 27010729

AN - SCOPUS:84961786714

SN - 1877-7821

VL - 42

SP - 46

EP - 52

JO - Cancer Epidemiology

JF - Cancer Epidemiology

ER -

Characterization of human papillomavirus antibodies in individuals with head and neck cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this